Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma

International Journal of Cancer. Journal International Du Cancer
Minna SopoSeppo Ylä-Herttuala

Abstract

We compared effects of antiangiogenic gene therapy with a combination of soluble sVEGFR-1, sVEGFR-2 and sVEGFR-3 to chemotherapy with carboplatin and paclitaxel and to antiangiogenic monoclonal anti-VEGF-antibody bevacizumab in an intraperitoneal ovarian cancer xenograft model in mice (n = 80). Gene therapy was also combined with chemotherapy. Therapy was initiated when sizable tumors were confirmed in magnetic resonance imaging (MRI). Adenovirus-mediated gene transfer was performed intravenously (2 × 109 pfu), while chemotherapy and monoclonal anti-VEGF-antibody were dosed intraperitoneally. The study groups were as follows: AdLacZ control (n = 21); combination of AdsVEGFR-1, -2 and -3 (n = 21); combination of AdsVEGFR-1, -2, -3 and paclitaxel (n = 9); bevacizumab (n = 14); paclitaxel (n = 9) and carboplatin (n = 5). Effectiveness was assessed by survival time and surrogate measures such as sequential MRI, immunohistochemistry, microvessel density and tumor growth. Antiangiogenic gene therapy combined with paclitaxel significantly prolonged the mean survival of mice (25 days) compared to the controls (15 days) and all other treatment groups (p = 0.001). Bevacizumab treatment did not have any significant effect on the survival....Continue Reading

References

Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S Ylä-HerttualaD Steinberg
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Jan 20, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·X LinS B Howell
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Limin HuRobert B Jaffe
Apr 25, 2006·Nature Reviews. Molecular Cell Biology·Anna-Karin OlssonLena Claesson-Welsh
May 3, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mari RakiAkseli Hemminki
Sep 28, 2006·Journal of Biochemistry and Molecular Biology·Masabumi Shibuya
Oct 27, 2006·International Journal of Cancer. Journal International Du Cancer·Yuji TakeiKeiya Ozawa
Feb 3, 2007·International Journal of Cancer. Journal International Du Cancer·Mamoru YamashitaFumitaka Kikkawa
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert A BurgerJoel I Sorosky
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen A CannistraWilliam McGuire
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seiji MabuchiMasahide Ohmichi
Dec 4, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hanna SallinenSeppo Yla-Herttuala
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ursula A MatulonisRichard T Penson
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward

❮ Previous
Next ❯

Citations

Feb 11, 2014·The American Journal of Pathology·Alessandra DecioDorina Belotti
May 13, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Laura TuppurainenSeppo Ylä-Herttuala
Jul 4, 2018·International Journal of Molecular Sciences·Ángela ÁyenHouria Boulaiz
Aug 3, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Tingting ZhuMinguang Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.